Premium
Coumarin‐containing hybrids and their antibacterial activities
Author(s) -
Feng Dongxu,
Zhang Aihua,
Yang Yuan,
Yang Peng
Publication year - 2020
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201900380
Subject(s) - dna gyrase , coumarin , novobiocin , antibacterial activity , pharmacophore , dna supercoil , antibiotics , moiety , chemistry , bacteria , microbiology and biotechnology , biology , biochemistry , dna , stereochemistry , escherichia coli , genetics , gene , organic chemistry , dna replication
Infections caused by Gram‐positive and ‐negative bacteria are one of the foremost causes of morbidity and mortality globally. Antibiotics are the mainstay of therapy for bacterial infections, but the emergence and wide spread of drug‐resistant pathogens have already become a huge issue for public healthcare systems. The coumarin moiety, which is ubiquitous in nature, could bind to the B subunit of DNA gyrase in bacteria and inhibit DNA supercoiling by blocking the ATPase activity; hence, coumarin derivatives possess potential antibacterial activity. Several coumarin‐containing hybrids such as coumermycin A1, clorobiocin, and novobiocin have already been used in clinical practice for the treatment of various bacterial infections; thus, it is conceivable that hybridization of the coumarin moiety with other antibacterial pharmacophores may provide opportunities for the development of novel antibiotics. This review outlines the advances in coumarin‐containing hybrids with antibacterial potential in the recent 5 years and the structure–activity relationships are also discussed.